Menu
We are a team of biotechnology entrepreneurs, physicians and highly talented scientists in the field of liver diseases and cell-based regenerative medicine
Cellaïon is a Belgian biotechnology company developing advanced therapies to repair tissues and regenerate organs, particularly the liver. Cellaïon targets life-threatening diseases.
We are located in the biotechnology valley of the Walloon region in Belgium.
We are a team of biotechnology entrepreneurs, physicians and highly talented scientists in the field of liver diseases and cell-based regenerative medicine.
Our strong intellectual property assets stem from our own research and from academic research at UCLouvain, aimed at generating new therapeutic products. The current portfolio offers intellectual property protection for our lead compound HepaStem® and its uses beyond 2040.
Our lead product, HepaStem®, is in advanced-stage clinical development in acute-on-chronic liver failure (ACLF), a life-threatening condition affecting more than 100,000 patients worldwide each year.
The liver has an immense capacity for regeneration, but this process is often overwhelmed by ongoing disease and tissue inflammation, leading to functional degradation of the organ and impairment of the regenerative process.
We, at Cellaïon, are developing HepaStem® with the aim of boosting the regenerative process and supporting the survival of the failing native liver.
HepaStem® has unique anti-inflammatory, immunomodulatory and regenerative properties. It is administered by a simple intravenous infusion.
